Kleo Pharmaceuticals, Inc.

Feb 06, 2020

Kleo Pharmaceuticals Receives IND Authorization to Proceed from FDA for its Multiple Myeloma Therapeutic

Dec 18, 2019

Kleo Pharmaceuticals to Present at Biotech Showcase 2020

Dec 02, 2019

Kleo Pharmaceuticals to Present at Piper Jaffray 31st Annual Healthcare Conference

Nov 06, 2019

Kleo Pharmaceuticals Presents Preclinical Data Supporting Development of its CD38-ARM(TM), a Novel Immuno-therapeutic, at American Society of Hematology (ASH) Annual Meeting

Nov 04, 2019

Kleo Pharmaceuticals Appoints Thomas J. Lynch, Jr., MD, as Chairman of the Board

Nov 04, 2019

Biohaven Statement Regarding Kleo Pharmaceuticals (Kleo): Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board

Oct 15, 2019

Kleo Pharmaceuticals to Present at 2019 BIO Investor Forum

Jun 18, 2019

Kleo Pharmaceuticals Announces a CD38 Targeting Antibody Recruiting Molecule (ARM(TM)) to Treat Multiple Myeloma as the First Clinical Candidate in its Partnership with PeptiDream